1) virtual MEDICA: heckel presentation on November, 16th, 2020
In the framework of a virtual healthcare show organized by BADEN-WÜRTTEMBERG INTERNATIONAL, there is a short 5 minute heckel presentation on November, 16th at 15:30, Pitching Session 3 "Treatments".
Please visit our partner Hydrosun in the virtual MEDICA exhibition space.
2) New publication: Retrospective analysis of 131 stage IV cancer patients treated with a combined protocol of low-dose checkpoint inhibitors, interleukin-2, and hyperthermia
In Cancer Immunology, Immunotherapy R. Kleef et al. have just published the paper
"Low-dose ipilimumab plus nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease: exploratory findings of a case series of 131 stage IV cancers – a retrospective study of a single institution".
Treatment consisted of locoregional- and whole-body hyperthermia, individually dose adapted interleukin 2 (IL-2) combined with low-dose ipilimumab (0.3 mg/kg) plus nivolumab (0.5 mg/kg). Fever-range whole-body hyperthermia was conducted with heckel-HT3000.
The authors conclude that "the immune-related adverse events profile of the combined treatment is safer than that of the established protocols without compromising efficacy".
Good response rates were observed even in cancer entities where immunotherapy has not yet been established as standard therapy.
본 게시물은 독일 heckel gmbH.에서 발행한 뉴스레터의 내용입니다.
